Remynd NV reported positive Phase IIa results for its investigational Alzheimer's drug REM-127, demonstrating improvements in cognition and reduced tau protein pathology by targeting calcium homeostasis in neurons. This is the first clinical evidence that modulating septin filaments can restore neuronal calcium channel function disrupted by tau. The trial was placebo-controlled and double-blinded, indicating robustness of results. Concurrently, Avidity Biosciences disclosed encouraging early-stage Duchenne muscular dystrophy data, showing disease stabilization and functional gains after one year of continuous treatment.